Top

Published in:

Open Access 08-12-2022 | NSCLC | Original Research Article

Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy

Authors: Antonello Veccia, Mariachiara Dipasquale, Stefania Kinspergher, Sara Monteverdi, Salvatore Girlando, Mattia Barbareschi, Orazio Caffo

Published in: Targeted Oncology | Issue 1/2023

Abstract

Background

KRAS is the most frequently mutated gene in non-small cell lung cancer (NSCLC), however conflicting data are available on its role as a biomarker.

Objective

The aim of our work was to investigate the impact of KRAS mutations on response and survival outcomes in advanced non-squamous NSCLC patients treated with immune checkpoint inhibitors alone or in combination with chemotherapy.

Patients and Methods

We retrospectively identified 119 patients, most of whom (58%) were KRAS wild type. For each patient we evaluated overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). An exploratory analysis was performed among KRAS mutated patients to investigate the impact of specific KRAS mutations on response and survival outcomes.

Results

After a median follow-up of 10.3 months, the median OS was 14.9 months (95% confidence interval [CI] 7.6–22.7) in wild-type KRAS patients versus 14.7 months (95% CI 8.0–19.5) in mutated KRAS patients (p = 0.529). No differences were detected between the two groups in terms of PFS and DCR. Patients with a KRAS G12C mutation reported survival and response outcomes that were not statistically different from those of patients with other KRAS mutations.

Conclusion

Our data confirmed that KRAS mutational status is not associated with survival and response outcomes in advanced non-squamous NSCLC patients treated with immunotherapy alone or combined with chemotherapy.

Yang H, Liang SQ, Schmid RA, Peng RW. New horizons in KRAS-mutant lung cancer: dawn after darkness. Front Oncol. 2019;9:953. https://doi.org/10.3389/fonc.2019.00953.CrossRefPubMedPubMedCentral

Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat Rev. 2020;84: 101974. https://doi.org/10.1016/j.ctrv.2020.101974.CrossRefPubMedPubMedCentral

Xie M, Xu X, Fan Y. KRAS-mutant non-small cell lung cancer: an emerging promisingly treatable subgroup. Front Oncol. 2021;11: 672612. https://doi.org/10.3389/fonc.2021.672612.CrossRefPubMedPubMedCentral

Hunter JC, Manandhar A, Carrosco MA, Gurbani D, Gondi S, Westover KD. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol Cancer Res. 2015;13(9):1325–35. https://doi.org/10.1158/1541-7786.MCR-15-0203.CrossRefPubMed

Biernacka A, Tsongalis PD, Peterson JD, de Abreu FB, Black CC, Gutmann EJ, et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 2016;209:195–8. https://doi.org/10.1016/j.cancergen.2016.03.001.CrossRefPubMedPubMedCentral

Davis AP, Cooper WA, Boyer M, Lee JH, Pavlakis N, Kao SC. Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations. Immunotherapy. 2021;13(11):941–52. https://doi.org/10.2217/imt-2021-0090.CrossRefPubMed

Lan B, Ma C, Zhang C, Chai S, Wang P, Ding L, et al. Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis. Oncotarget. 2018;9(7):7684–99. https://doi.org/10.18632/oncotarget.23969.CrossRefPubMedPubMedCentral

Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, et al. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Cancer. 2019;125(7):1038–49. https://doi.org/10.1002/cncr.31871.CrossRefPubMed

Ghimessy A, Radeczky P, Laszlo V, Hegedus B, Renyi-Vamos F, Fillinger J, et al. Current therapy of KRAS-mutant lung cancer. Cancer Metastasis Rev. 2020;39(4):1159–77. https://doi.org/10.1007/s10555-020-09903-9.CrossRefPubMedPubMedCentral

10.

Gu M, Xu T, Chang P. KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas. Ther Adv Med Oncol. 2021;13: 17588359211006950. https://doi.org/10.1177/17588359211006950.CrossRefPubMedPubMedCentral

11.

Liu C, Zheng S, Jin R, Wang X, Wang F, Zang R, et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 2020;470:95–105. https://doi.org/10.1016/j.canlet.2019.10.027.CrossRefPubMed

12.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–8. https://doi.org/10.1093/annonc/mdz167.CrossRefPubMedPubMedCentral

13.

R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021. https://www.R-project.org/.

14.

Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis. J Thorac Oncol. 2016;12(2):403–7. https://doi.org/10.1016/j.jtho.2016.10.007.CrossRefPubMed

15.

Kim JH, Kim HS, Kim BJ. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis and review. Oncotarget. 2017;8(29):48248–52. https://doi.org/10.18632/oncotarget.17594.CrossRefPubMedPubMedCentral

16.

Landre T, Justeau G, Assié JB, Chouahnia K, Davoine C, Taleb C, et al. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer Immunol Immunother. 2022;71:719–26. https://doi.org/10.1007/s00262-021-03031-1.CrossRefPubMed

17.

Guaitoli G, Tiseo M, Di Maio M, Friboulet L, Facchinetti F. Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res. 2021;10(6):2890–916. https://doi.org/10.21037/tlcr-20-941.CrossRefPubMedPubMedCentral

18.

Torralvo J, Friedlaender A, Achard V, Addeo A. The activity of immune checkpoint inhibition in KRAS mutated non-small cell lung cancer: a single centre experience. Cancer Genom Proteom. 2019;16(6):577–82. https://doi.org/10.21873/cgp.20160.CrossRef

19.

Gianoncelli L, Spitaleri G, Passaro A, Radice D, Fumagalli C, Del Signore E, et al. Efficacy of anti-PD1/PD-L1 therapy (IO) in KRAS mutant non-small cell lung cancer patients: a retrospective analysis. Anticancer Res. 2020;40(1):427–33. https://doi.org/10.21873/anticanres.13970.CrossRefPubMed

20.

Noordhof AL, DamhuisDamhuis RAM, Hendriks LEL, de Langen AJ, Timens W, Venmans BJW, et al. Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. Lung Cancer. 2021;155:163–9. https://doi.org/10.1016/j.lungcan.2021.04.001.CrossRefPubMed

21.

Finn SP, Addeo A, Dafni U, Thunnissen E, Bubendorf L, Madsen LB, et al. Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol. 2021;16(6):990–1002. https://doi.org/10.1016/j.jtho.2021.02.016.CrossRefPubMed

22.

Spira AI, Tu H, Aggarwal S, Hsu H, Carrigan G, Wang X, et al. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. Lung Cancer. 2021;159:1–9. https://doi.org/10.1016/j.lungcan.2021.05.026.CrossRefPubMed

23.

Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207–17. https://doi.org/10.1056/NEJMoa1917239.CrossRefPubMedPubMedCentral

24.

Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371–81. https://doi.org/10.1056/NEJMoa2103695.CrossRefPubMedPubMedCentral

25.

Amgen. Study to compare AMG 510 “Proposed INN Sotorasib” with docetaxel in non small cell lung cancer (NSCLC) (CodeBreak 200). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04303780.

26.

Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32(9):1101–10. https://doi.org/10.1016/j.annonc.2021.06.001.CrossRefPubMed

Title: Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy
Authors: Antonello Veccia
Mariachiara Dipasquale
Stefania Kinspergher
Sara Monteverdi
Salvatore Girlando
Mattia Barbareschi
Orazio Caffo
Publication date: 08-12-2022
Publisher: Springer International Publishing
Keywords: NSCLC
NSCLC
Checkpoint Inhibitors
Cytostatic Therapy
Published in: Targeted Oncology / Issue 1/2023
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-022-00934-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Patients and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast

Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan

Keynote webinar | Spotlight on antibody–drug conjugates in cancer